Prognostic Impact of Immune-Related Adverse Events As First-Line Therapy for Metastatic Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. Takuhisa Nukaya , Kiyoshi Takahara , Atsuhiko Yoshizawa , Masanobu Saruta , Yusuke Yano , Takaya Ohno , Taizo Uchimoto , Wataru Fukuokaya , Takahiro Adachi , Shogo Yamazaki , Satoshi Tokushige , Kazuki Nishimura , Takuya Tsujino , Keita Nakamori , Shutaro Yamamoto , Kosuke Iwatani , Fumihiko Urabe , Keiichiro Mori , Takafumi Yanagisawa , Shunsuke Tsuduki , Yosuke Hirasawa , Takeshi Hashimoto , Kazumasa Komura , Teruo Inamoto , Jun Miki , Takahiro Kimura , Yoshio Ohno , Haruhito Azuma , Ryoichi Shiroki CLINICAL GENITOURINARY CANCER（2024）
关键词
Metastatic renal cell carcinoma, Immune-related adverse events, Nivolumab plus ipilimumab, OS predictors, First-line therapy
AI 理解论文
溯源树
样例
